Protara Therapeutics (TARA) VP Fry has RSU shares withheld for taxes
Rhea-AI Filing Summary
Protara Therapeutics VP, Controller Hannah Fry reported a tax-related share withholding. On 01/26/2026, 1,457 shares of Protara Therapeutics common stock were withheld by the company at a price of $6.67 per share to cover income tax obligations tied to the vesting of a restricted stock unit award originally granted on January 24, 2025. After this withholding, Fry beneficially owned 42,723 shares of Protara common stock in direct ownership.
Positive
- None.
Negative
- None.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise Price or Tax Liability | Common Stock | 1,457 | $6.67 | $10K |
Footnotes (1)
- F1. Represents shares withheld by the Issuer to satisfy income tax obligations associated with the vesting of a Restricted Stock Unit Award granted to the Reporting Person on January 24, 2025.
FAQ
What insider transaction did Protara Therapeutics (TARA) report for Hannah Fry?
Protara Therapeutics reported that VP, Controller Hannah Fry had 1,457 common shares withheld on 01/26/2026 to cover income tax obligations related to a vesting restricted stock unit award.
Was the Protara Therapeutics (TARA) Form 4 transaction an open market sale?
No. The Form 4 shows a transaction coded F, meaning shares were withheld by the issuer to satisfy tax obligations from RSU vesting, rather than an open market sale.
What triggered the tax withholding transaction reported in the Protara (TARA) Form 4?
The withholding relates to the vesting of a Restricted Stock Unit Award that was granted to Hannah Fry on January 24, 2025, which created income tax obligations.
What is Hannah Fry’s role at Protara Therapeutics (TARA)?
Hannah Fry is an officer of Protara Therapeutics, serving as VP, Controller, as indicated in the Form 4.
AI-generated analysis. How Rhea-AI works. Not financial advice.